Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13243255 | 1.00 | DRD2 (0.42) | DRD2SLC6A4ADRA1DADRA1AADRA1B | |
| SCHEMBL3026960 | 0.87 | DRD2 (0.42) | DRD2SLC6A4ADRA1DADRA1AADRA1B | |
| SCHEMBL8122818 | 0.87 | DRD2 (0.42) | DRD2SLC6A4ADRA1DADRA1AADRA1B | |
| SCHEMBL3032121 | 0.87 | DRD2 (0.42) | DRD2SLC6A4ADRA1DADRA1AADRA1B | |
| SCHEMBL13222379 | 0.87 | DRD2 (0.42) | DRD2SLC6A4ADRA1DADRA1AADRA1B | |
| Water SCHEMBL3032078 | 0.86 | DRD2 (0.41) | DRD2SLC6A4ADRA1DADRA1AADRA1B | |
| SCHEMBL15031120 | 0.84 | DRD2 (0.42) | DRD2SLC6A4ADRA1DADRA1AADRA1B | |
| SCHEMBL10305227 | 0.80 | CREBBP (0.40) | DRD2SLC6A4ADRA1DADRA1AADRA1B | |
| SCHEMBL5957074 | 0.79 | DRD2 (0.45) | DRD2SLC6A4ADRA1DADRA1AADRA1B | |
| Aplindore SCHEMBL3192098 | 0.78 | DRD2 (0.68) | DRD2SLC6A4DRD4DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1726592-A1 | Dioxino derivatives and their use as dopanine agonists | Wyeth a Corporation of the State of Delaware (US) | 2006-11-29 | — | — | EP | claimed |
| EP-1375503-A1 | Dioxino derivatives and their use as dopanine agonists | Wyeth (US) | 2004-01-02 | — | — | EP | claimed |
| JP-9249671-A | — | — | None | — | — | JP | disclosed |
| US-8466296-B2 | Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones | LIGAND PHARMACEUTICALS (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466296-B2 | Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones | LIGAND PHARMACEUTICALS (US) | 2013-06-18 | — | — | US | disclosed |
| US-20100217012-A1 | COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONES | NEUROGEN CORPORATION (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100217012-A1 | COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONES | NEUROGEN CORPORATION (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2008118935-A1 | COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-E]INDOL-8-ONES | NEUROGEN CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118935-A1 | COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-E]INDOL-8-ONES | NEUROGEN CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1375503-B1 | Dioxino derivatives and their use as dopanine agonists | WYETH CORP (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1726592-A1 | Dioxino derivatives and their use as dopanine agonists | Wyeth a Corporation of the State of Delaware (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-1375503-A1 | Dioxino derivatives and their use as dopanine agonists | Wyeth (US) | 2004-01-02 | — | — | EP | disclosed |
| EP-0932609-B1 | AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO 2,3-e]INDOL-8-ONE | WYETH CORP (US) | 2003-05-14 | — | — | EP | disclosed |
| CN-1084748-C | Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]-indol-8-ones and derivatives | AERMICAN HOME PRODUCTS CORP (US) | 2002-05-15 | — | — | CN | disclosed |
| EP-0932609-A1 | AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO 2,3-e]INDOL-8-ONE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998016530-A1 | AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-04-23 | — | — | WO | disclosed |
| JP-H09249671-A | AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO(2,3-E)-INDOL-8-ONE AND ITS DERIVATIVE | AMERICAN HOME PROD CORP | 1997-09-22 | — | — | JP | disclosed |
| CN-1155546-A | Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]-indol-8-ones and derivatives | AMERICAN HOME PROD (US) | 1997-07-30 | — | — | CN | disclosed |
| EP-0771800-A2 | Dioxino derivatives and their use as dopamine agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217012-A1 | COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONES | MTNR1A, HTR3C, MTNR1B | DRD2 27/4885SLC6A4 527/4885ADRA1D 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.